Recombinant Human SMAC/Diablo
Catalog Number: 789-SM

DESCRIPTION

Source E. coli-derived human SMAC/Diablo protein
Ala56-Asp239, with a C-terminal 6-His tag
Accession # Q9NR28

N-terminal Sequence Analysis
Ala56

Predicted Molecular Mass
22 kDa

SPECIFICATIONS

SDS-PAGE 23 kDa, reducing conditions

Activity Measured by its ability to reverse the inhibition of DEVD-AFC cleavage activity in cell extracts activated by addition of cytochrome c and dATP.
The IC_{50} for reversal of XIAP-BIR3 (50 nM) inhibition of DEVD-AFC cleavage in activated cell extracts is <2,000 nM.
Optimal dilutions should be determined by each laboratory for each application.

Purity >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Formulation Supplied as a 0.2 μm filtered solution in HEPES and NaCl. See Certificate of Analysis for details.

Activity Assay Protocol

Materials
- Jurkat E6 wild type cell extracts (see supplementary methods for preparation)
- Extraction Buffer: 50 mM HEPES, 10 mM KCl, 5 mM EGTA, 1 mM MgCl₂, 0.2% CHAPS, 0.2 mM DTT, pH 7.5
- Assay Buffer: 10 mM HEPES, 0.5 mM EGTA, 5 mM DTT, 10% Glycerol, pH 7.5
- Formulation Buffer: 25 mM HEPES, 0.1 M KCl, pH 7.5
- Recombinant Human SMAC/Diablo (rhSMAC) (Catalog # 789-SM)
- Recombinant Human XIAP BIR3 Domain (rhXIAP) (Catalog # 895-XB)
- Cytochrome C, Bovine heart (Sigma, Catalog # C3131), 2 mg/mL stock in deionized water
dATP (Sigma, Catalog # D6500), 10 mM stock adjusted to pH 7.5 with NaOH
Substrate: Ac-Asp-Glu-Val-Asp-AFC (DEVD-AFC) (MP Biomedicals, Catalog # AFC138), 10 mM stock in DMSO
F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent

Assay
Note: All reagents and assay components should be kept on ice until use.
1. Thaw cell extracts and centrifuge in a microcentrifuge at 14,000 rps for 5 minutes at 4 °C. Transfer supernatants to chilled tubes and use within 1 hour.
2. Prepare a 250 nM stock of rhXIAP (BIR3) (MW: 13.0 KDa) in Formulation Buffer.
3. Prepare a curve of rhSMAC (MW: 21.6 KDa) in Formulation Buffer. Make the following serial dilutions: 50,000, 15,000, 7500, 3000, 1500, 600, 300, 120 and 60 nM. Note: High point may not be achievable depending on lot received.
4. Prepare the activator mixture by combining equal volumes of 2 mg/mL Cytochrome C and 10 mM dATP for working concentrations of 1 mg/mL and 5 mM, respectively.
5. Prepare reaction mixtures in tubes by combining 5 μL of the cytochrome C/dATP activator mixture. Also, prepare the following controls:
   a. Total Control: 10 μL of Extraction Buffer, 10 μL of cell extract supernatant, and 5 μL of the cytochrome C/dATP activator mixture.
   b. Inactive Control: 15 μL of Extraction Buffer and 10 μL of cell extract supernatant. The total reaction volume is 25 μL.
   c. rhXIAP (BIR3) only Control: 5 μL of Extraction Buffer, 5 μL of rhXIAP (BIR3), 10 μL of cell extract supernatant, and 5 μL of the cytochrome C/dATP activator mixture.
6. Incubate for 60 minutes at 30 °C.
7. After incubation, add 100 μL of Assay Buffer to each vial for a five-fold dilution. Mix briefly.
8. Dilute Substrate to 100 μM in Assay Buffer.
9. In a plate load 50 μL of diluted incubated reaction mixtures and start the reaction by adding 50 μL of 100 μM Substrate.
10. Read at excitation and emission wavelengths of 400 nm and 505 nm, respectively, in kinetic mode for 5 minutes.
11. Derive the 50% inhibiting concentration (IC_{50}) of rhSMAC by plotting normalized activity vs. reaction concentration of rhSMAC with 4-PL fitting.
12. Normalized activity may be determined using the following equation:
   \[
   \text{% Normalized Activity} = \frac{\text{Sample (RFU/min)} - \text{Inactive Control (RFU/min)}}{\text{Total Control (RFU/min)}} \times 100\%
   \]

Final Assay Conditions Per Reaction:
- rhSMAC curve: 10,000, 3000, 1500, 600, 300, 120 and 60 nM

PREPARATION AND STORAGE

Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 6 months from date of receipt, -20 to -70 °C as supplied.
- 3 months, -20 to -70 °C under sterile conditions after opening.

Rev. 10/15/2018 Page 1 of 2
BACKGROUND
SMAC (second mitochondrion derived activator of caspase)/Diablo promotes caspase activation by interacting with the inhibitor of apoptosis (IAP) proteins in the cytochrome c/Apaf-1/caspase-9 pathway.

SUPPLEMENTARY METHODS
SMAC/Diablo can reverse rhXIAP inhibition of DEVD-AFC cleavage in activated cell lysates.
Recombinant Human XIAP Full Length (Catalog # 822-XF) can be used in the Activity Assay Protocol in place of rhXIAP (BIR3). The IC_{50} for reversal of XIAP (500 nM) inhibition of DEVD-AFC cleavage in activated cell extracts is typically 500-1500 nM.

References: